<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the clinical utility of FISH for del(5q) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, we first compared FISH for 5q31 (EGR1) and 5q33 (CSF1R) in 51 myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> containing del(5q) by metaphase cytogenetics </plain></SENT>
<SENT sid="1" pm="."><plain>Next, EGR1 FISH was compared to metaphase cytogenetics alone in 269 cases of known or suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>These studies show that while metaphase cytogenetics alone can detect del(5q) in most cases, FISH is particularly useful in cases with suboptimal growth </plain></SENT>
<SENT sid="3" pm="."><plain>EGR1 FISH detects del(5q) in a broad variety of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, including at least most cases of <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>, while studies for CSF1R add little to the diagnostic yield </plain></SENT>
</text></document>